Navigation Links
Renal denervation treats resistant hypertension in real world patient populations
Date:8/27/2012

Munich, Germany August 27 2012: Renal denervation successfully treats patients with resistant hypertension in real world patient populations, according to a study presented at ESC Congress 2012. The findings were presented by Dr Darren Mylotte from France.

Transcatheter renal denervation represents a novel therapy for treating patients with treatment resistant hypertension, a condition which greatly increases the risk of myocardial infarction and stroke.

"The Symplicity Hypertension I and II studies have suggested that this procedure significantly lowers blood pressure in these patients with few remaining options in terms of treatment," said Dr Mylotte. "However, patients included in clinical trials are often highly selected, and therefore may not reflect the patient encountered by physicians on a day-to-day basis. As such, the results of these trials may not be applicable to less-selected patient populations."

In light of this potential problem, the investigators sought to evaluate the effect of transcatheter renal denervation in a group of patients with resistant hypertension in their own clinical practice at The Institut Cardiovasculaire de Paris Sud, Paris, France.

They intended to perform transcatheter renal denervation on 35 consecutive patients referred to the service with resistant hypertension. The study used the same definition as the Symplicity trials to define resistant hypertension (1).

Among these patients, 36.5% were female, 36.4% were diabetic, and 15.2% had kidney dysfunction. Baseline office blood pressure (BP) was 181.121.9 /100.816.8 mmHg, despite an average of 4.61.0 medications per patient. Successful bilateral sympathetic denervation was performed in 33 out of 35 patients (1 patient was not treated due to a stenosis of the renal artery; 1 patient had treatment on one side only, as multiple small renal arteries were found on the other side). No procedural complications occurred.

At 6-m
'/>"/>

Contact: ESC Press Office
press@escardio.org
European Society of Cardiology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Newborn Screening May Miss Adrenal-Gland Disorder
2. Broken heart syndrome protects the heart from adrenaline overload
3. Renal denervation gives better outcomes than drugs in advanced heart failure
4. Intense light prevents, treats heart attacks
5. Novel radiation therapy safely treats prostate cancer and lowers the risk of recurrence
6. Kinase test may yield big gains for drug-resistant cancers
7. New drug strategy attacks resistant leukemia and lymphoma
8. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
9. New Medicine Might Fight Drug-Resistant TB, Study Says
10. Antibiotic-Resistant Gonorrhea Spreading: WHO
11. Rare Drug-Resistant Bacteria Spotted in U.S. Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... MMAR Medical is pleased to announce their ... regular customers to enjoy several perks and benefits when ... wholesale license. It’s a great choice for independent athletes, ... who regularly purchase medical braces but could use a ... active lifestyle or those of your club, group or ...
(Date:8/28/2014)... The need for larger space has become more ... The new location - 4700 Bryant Irvin Court, Fort Worth, ... space than TLC had in the past, as well as ... our new location because it represents a good fit for ... in size compared to the current one, the building itself ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Aeroflow ... to acquire as part of a strategic expansion ... is positioned for taking ownership of new businesses ... increase economies of scale. , Last week, the ... with Hometown Respiratory to increase service in the ...
(Date:8/27/2014)... 2014 According to a new market ... Market (Neurosurgical Navigation Systems, ENT Navigation Systems and Orthopedic ... Trends and Forecast 2014 - 2020", the global surgical ... in 2013 and is expected to grow at a ... an estimated value of USD 295.5 million in 2020. ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 DiaSorin has ... Utility of 1,25 Dihydroxyvitamin D,” will feature guest speaker ... Penny George Institute for Health and Healing Integrative Medicine. ... the Penny George Institute for Health and Healing and ... Health Care, Minneapolis, Minnesota. He also serves as a ...
Breaking Medicine News(10 mins):Health News:MMAR Medical Announces Customer Membership Program 2Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 3
... gives new meaning to the word transformative, researchers from ... are integrating some of the best practices of industry ... propel the development of innovative cancer treatments from the ... Cancer Center has initiated the Translational Research Acceleration Collaboration ...
... Foundation for a,Healthy Florida, the philanthropic affiliate of ... approved $951,486 in grants to be awarded this,winter ... needs in their communities., "The Blue Foundation ... to quality health-related services for Floridians who are ...
... lives could be,saved over the next five years through ... the 30 hardest hit countries in,Africa, according to a ... rapid scale-up would increase annual economic output,by as much ... cases, and,free up 427,000 needed hospital beds over five ...
... MIAMI, Jan. 25 OPKO Health, Inc. (Amex: ... and Richard C.,Pfenniger, Jr. to its Board of Directors. ... David Eichler. Mr. Pfenniger was,appointed to fill the vacancy ... a newly created Board position., "The addition of ...
... Calif., Jan. 25 IPC The,Hospitalist Company, Inc. (Nasdaq: ... yesterday the initial public offering of 5,200,000,shares of its ... $16.00 per share.,The Company has agreed to sell 3,300,000 ... to sell the remaining 1,900,000 shares of,common stock. The ...
... as 30,000 deaths each year, study says , , FRIDAY, ... greatly reduce their risk of developing ovarian cancer, and the ... study confirms. , The use of oral contraceptives has long ... The authors of the new study say their findings show ...
Cached Medicine News:Health News:ITRAC on track and bridging gap between academic research and applied discovery 2Health News:ITRAC on track and bridging gap between academic research and applied discovery 3Health News:Eleven Florida Nonprofit Organizations to Receive Grants Totaling Nearly $1 Million From The Blue Foundation 2Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 2Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 3Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 4Health News:OPKO Health Announces Changes to Board of Directors 2Health News:OPKO Health Announces Changes to Board of Directors 3Health News:IPC The Hospitalist Company, Inc. Prices Initial Public Offering 2Health News:Oral Contraceptives Cut Ovarian Cancer Risk 2Health News:Oral Contraceptives Cut Ovarian Cancer Risk 3
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Orthopedic Soft ... http://www.reportlinker.com/p02316671/Global-Orthopedic-Soft-Tissue-Repair-Devices-Market-2014-2018.html About Orthopedic ... the mass of cells that connect, support, or ... soft tissues such as tendons, ligaments, cartilage, fascia, ...
(Date:8/27/2014)... 2014 Decision Resources Group finds that the ... Memphis health system and hospital sector in ... rivals Methodist Le Bonheur Healthcare and Baptist Memorial Health ... patient care. In addition, a national contract recently signed ... plan enrollment in the Memphis ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Heart ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html About Heart ... in the human heart which control the flow ... affected with heart valve diseases such as valvular ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Memphis-area Health Systems Turn Attention to Clinical Integration 2Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
... on Smart Cards. Insert the card and turn ... turns itself off after the programmed time. The ... of treatments. Simply provide your patient with the ... progress on the next visit.,The initial set of ...
... battery operated dual-channel therapy system designed for use ... 4 Conti also includes a programme for treating ... 4 Conti provokes a contraction of the pelvic ... muscles need exercising. In URGE incontinence, ELPHA 4 ...
... disposable template is designed for ... eliminate the need for cleaning. ... premium silicone molded over a ... needle placement while maintaining needle ...
... is designed for use with the ... prostate brachytherapy. Please be sure that ... the graphics on the Reusable Template. ... from lower surface which fits into ...
Medicine Products: